$1.38
-0.035-2.47%
Last update: Nov 5, 5:16 AM
Autolus Therapeutics PLC (AUTL) Stock Price, Quote, News & History
AUTLNASDAQ
U.K.'s NICE issues draft guidance recommending Autolus' Aucatzyl for adult r/r B-ALL, setting up imminent NHS launch and broader patient access.
You can purchase shares of Autolus Therapeutics (NASDAQ:AUTL) through any online brokerage.
Other companies in Autolus Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Autolus Therapeutics has a consensus price target of $9.22.
The stock price for Autolus Therapeutics (NASDAQ: AUTL) is $1.41 last updated November 5, 2026 at 5:16 AM EST.
There are no upcoming dividends for Autolus Therapeutics.
Autolus Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Autolus Therapeutics.
Autolus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5,...
